Rx Risk Descriptions Need To Be Standardized, FDA’s Galson Tells CERTs
Executive Summary
The standardization of risk expressions to compare drugs would be a desirable risk management tool, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, suggested at a recent CERTs meeting
You may also be interested in...
FDA Should Validate Effectiveness Of Risk Management Tools, PhRMA Says
FDA risk management programs should be evaluated by the agency to determine the value of their implementation, the Pharmaceutical Research & Manufacturers of America maintained during a public workshop on risk management April 10
FDA Should Validate Effectiveness Of Risk Management Tools, PhRMA Says
FDA risk management programs should be evaluated by the agency to determine the value of their implementation, the Pharmaceutical Research & Manufacturers of America maintained during a public workshop on risk management April 10
Drug Benefit Defined By Dose-Response Relationships, CERTs Suggests
Establishing the correct dose-response relationship for drugs is crucial to defining drug benefit, the Centers for Education & Research on Therapeutics suggested